Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Extracellular Vesicles Enriched in Connexin 43 Promote a Senescent Phenotype in Bone and Synovial Cells Contributing to Osteoarthritis Progression

  • Varela-Eirín, Marta
  • Carpintero-Fernández, Paula
  • Guitián-Caamaño, Amanda
  • Varela Vázquez, Adrián
  • García-Yuste, Alejandro
  • Sánchez-Temprano, Agustín
  • Bravo López, Susana Belén
  • Yáñez-Cabanas, José
  • Fonseca, Eduardo
  • Largo, R
  • Mobasheri, Ali
  • Caeiro, José Ramón
  • Mayán, María D.
[Abstract] The accumulation of senescent cells is a key characteristic of aging, leading to the progression of age-related diseases such as osteoarthritis (OA). Previous data from our laboratory has demonstrated that high levels of the transmembrane protein connexin 43 (Cx43) are associated with a senescent phenotype in chondrocytes from osteoarthritic cartilage. OA has been reclassified as a musculoskeletal disease characterized by the breakdown of the articular cartilage affecting the whole joint, subchondral bone, synovium, ligaments, tendons and muscles. However, the mechanisms that contribute to the spread of pathogenic factors throughout the joint tissues are still unknown. Here, we show for the first time that small extracellular vesicles (sEVs) released by human OA-derived chondrocytes contain high levels of Cx43 and induce a senescent phenotype in targeted chondrocytes, synovial and bone cells contributing to the formation of an inflammatory and degenerative joint environment by the secretion of senescence-associated secretory associated phenotype (SASP) molecules, including IL-1ß and IL-6 and MMPs. The enrichment of Cx43 changes the protein profile and activity of the secreted sEVs. Our results indicate a dual role for sEVs containing Cx43 inducing senescence and activating cellular plasticity in target cells mediated by NF-kß and the extracellular signal-regulated kinase 1/2 (ERK1/2), inducing epithelial-to-mesenchymal transition (EMT) signalling programme and contributing to the loss of the fully differentiated phenotype. Our results demonstrated that Cx43-sEVs released by OA-derived chondrocytes spread senescence, inflammation and reprogramming factors involved in wound healing failure to neighbouring tissues, contributing to the progression of the disease among cartilage, synovium, and bone and probably from one joint to another. These results highlight the importance for future studies to consider sEVs positive for Cx43 as a new biomarker of disease progression and new target to treat OA., This work was supported in part through funding from Health Institute ‘Carlos III’ (ISCIII, Spain), the European Regional Development Fund, ‘A way of making Europe’ from the European Union (to MDM): grant PI19/00145; a grant from the Joint Transnational Call for Proposals for “European Innovative Research & Technological Development Projects in Nanomedicine” EURONANOMED III (AC21_2/00026) (to MDM); a grant from Xunta de Galicia (IN607B2020/12) (to MDM) and from H2020, Future and Emerging Technologies (grant 858014 “PANACHE”) to MDM. MV-E was funded with a predoctoral (ED481A-2015/188) and post-doctoral fellowship (IN606B-2019/004) from Xunta de Galicia. AG-C was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. PC-F was funded with a post-doctoral fellowship and a grant from Xunta de Galicia (INB606B 2017/014 and IN606C 2021/006). We thank members of the CellCOM group for helpful technical suggestion, María Dolores Álvarez Alvariño (CHUS) for generously collecting tissue samples in the operating room after surgery and Arantxa Tabernero (INCYL, University of Salamanca) for kindly providing the human Cx43 plasmid used in this study, Xunta de Galicia; IN607B2020/12, Xunta de Galicia; ED481A-2015/188, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; INB606B 2017/014, Xunta de Galicia; IN606C 2021/006
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

New Therapeutic Strategies for Osteoarthritis by Targeting Sialic Acid Receptors

  • Carpintero-Fernández, Paula
  • Varela-Eirín, Marta
  • Lacetera, Alessandra
  • Gago-Fuentes, Raquel
  • Fonseca, Eduardo
  • Martín-Santamaría, Sonsoles
  • Mayán, María D.
[Abstract] Osteoarthritis (OA) is the most common degenerative joint disease characterized by articular cartilage degradation and joint degeneration. The articular cartilage is mainly formed by chondrocytes and a collagen-proteoglycan extracellular matrix that contains high levels of glycosylated proteins. It was reported that the shift from glycoproteins containing α-2,6-linked sialic acids to those that contain α-2,3 was associated with the onset of common types of arthritis. However, the pathophysiology of α-2,3-sialylation in cartilage has not been yet elucidated. We show that cartilage from osteoarthritic patients expresses high levels of the α-2,3-sialylated transmembrane mucin receptor, known as podoplanin (PDPN). Additionally, the Maackia amurensis seed lectin (MASL), that can be utilized to target PDPN, attenuates the inflammatory response mediated by NF-kB activation in primary chondrocytes and protects human cartilage breakdown ex vivo and in an animal model of arthritis. These findings reveal that specific lectins targeting α-2,3-sialylated receptors on chondrocytes might effectively inhibit cartilage breakdown. We also present a computational 3D molecular model for this interaction. These findings provide mechanistic information on how a specific lectin could be used as a novel therapy to treat degenerative joint diseases such as osteoarthritis., This work was funded by the Spanish Society for Rheumatology (SER-2013) and the Spanish Society for Research on Bone and Mineral Metabolism (FEIOMM-2016) (to M.D.M.) and by the grant PI13/00591, PI16/00035, and PI19/00145 from the Health Institute “Carlos III” (ISCIII, Spain) and was cofinanced by the European Regional Development Funds, “A way of making Europe” from the European Union (to M.D.M.). Paula Carpintero-Fernández has a postdoctoral fellowship from Xunta de Galicia (IN606B 2017/014) Two predoctoral fellowships from Xunta de Galicia to Marta Varela-Eirin (ED481A 2015/188) and Raquel Gago-Fuentes (PRE/2012/165) and from University of A Coruña—INDITEX and CICA-INIBIC (AGRUP2015/05). The Spanish Ministry for Economy and Competitiveness (MINECO) grants CTQ2014-57141-R and CTQ2017-88353-R (to S.M.-S.) is gratefully acknowledged., Xunta de Galicia; IN606B 2017/014, Xunta de Galicia; ED481A 2015/188, Xunta de Galicia; PRE/2012/165
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Senolytic Activity of Small Molecular Polyphenols from Olive Restores Chondrocyte Redifferentiation and Promotes a Pro-Regenerative Environment in Osteoarthritis

  • Varela-Eirín, Marta
  • Carpintero-Fernández, Paula
  • Sánchez-Temprano, Agustín
  • Varela Vázquez, Adrián
  • Luis Paíno, Carlos
  • Casado-Díaz, Antonio
  • Calañas-Continente, Alfonso
  • Mato-Abad, Virginia
  • Fonseca, Eduardo
  • Kandouz, Mustapha
  • Blanco, Alfonso
  • Caeiro, José Ramón
  • Mayán, María D.
[Abstract] Articular cartilage and synovial tissue from patients with osteoarthritis (OA) show an overactivity of connexin43 (Cx43) and accumulation of senescent cells associated with disrupted tissue regeneration and disease progression. The aim of this study was to determine the effect of oleuropein on Cx43 and cellular senescence for tissue engineering and regenerative medicine strategies for OA treatment. Oleuropein regulates Cx43 promoter activity and enhances the propensity of hMSCs to differentiate into chondrocytes and bone cells, reducing adipogenesis. This small molecule reduce Cx43 levels and decrease Twist-1 activity in osteoarthritic chondrocytes (OACs), leading to redifferentiation, restoring the synthesis of cartilage ECM components (Col2A1 and proteoglycans), and reducing the inflammatory and catabolic factors mediated by NF-kB (IL-1ß, IL-6, COX-2 and MMP-3), in addition to lowering cellular senescence in OACs, synovial and bone cells. Our in vitro results demonstrate the use of olive-derived polyphenols, such as oleuropein, as potentially effective therapeutic agents to improve chondrogenesis of hMSCs, to induce chondrocyte re-differentiation in OACs and clearing out senescent cells in joint tissues in order to prevent or stop the progression of the disease., Xunta de Galicia; IN607B 2017/21, Xunta de Galicia; ED481A-2015/188, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; IN606B-2017/014, This work was supported in part through funding from the Spanish Foundation for Research on Bone and Mineral Metabolism (FEIOMM), grant PRECIPITA-2015-000139 from the FECYT-Ministry of Economy and Competitiveness (to M.D.M.), grant PI16/00035 and PI19/00145 from the Health Institute ‘Carlos III’ (ISCIII, Spain), the European Regional Development Fund, ‘A way of making Europe’ from the European Union (to M.D.M.) and a grant from Xunta de Galicia IN607B 2017/21 (to M.D.M.). M.V.-E. was funded with a predoctoral (ED481A-2015/188) and a postdoctoral fellowship (IN606B-2019/004) from Xunta de Galicia. P.C.-F. was funded with a postdoctoral fellowship (IN606B-2017/014) from Xunta de Galicia.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Genome Wide CRISPR/Cas9 Screen Identifies the Coagulation Factor IX (F9) as a Regulator of Senescence

  • Carpintero-Fernández, Paula
  • Borghesan, Michela
  • Eleftheriadou, Olga
  • Pan-Castillo, Belén
  • Fafián-Labora, J.A.
  • Mitchell, Tom P.
  • Yuste, Alejandro
  • Ogrunc, Muge
  • Nightingale, Thomas D.
  • Mayán, María D.
  • O'Loghlen, Ana
[Abstract] During this last decade, the development of prosenescence therapies has become an attractive strategy as cellular senescence acts as a barrier against tumour progression. In this context, CDK4/6 inhibitors induce senescence and reduce tumour growth in breast cancer patients. However, even though cancer cells are arrested after CDK4/6 inhibitor treatment, genes regulating senescence in this context are still unknown limiting their antitumour activity. Here, using a functional genome-wide CRISPR/Cas9 genetic screen we found several genes that participate in the proliferation arrest induced by CDK4/6 inhibitors. We find that downregulation of the coagulation factor IX (F9) using sgRNA and shRNA prevents the cell cycle arrest and senescent-like phenotype induced in MCF7 breast tumour cells upon Palbociclib treatment. These results were confirmed using another breast cancer cell line, T47D, and with an alternative CDK4/6 inhibitor, Abemaciclib, and further tested in a panel of 22 cancer cells. While F9 knockout prevents the induction of senescence, treatment with a recombinant F9 protein was sufficient to induce a cell cycle arrest and senescence-like state in MCF7 tumour cells. Besides, endogenous F9 is upregulated in different human primary cells cultures undergoing senescence. Importantly, bioinformatics analysis of cancer datasets suggest a role for F9 in human tumours. Altogether, these data collectively propose key genes involved in CDK4/6 inhibitor response that will be useful to design new therapeutic strategies in personalised medicine in order to increase their efficiency, stratify patients and avoid drug resistance., This paper was funded by the BBSRC (BB/P000223/1), the MRC (MR/K501372/1), The Royal Society (RG170399) and Barts Charity (MGU0497 and G-002158) grants to A.O. M.M. was funded by PI19/00145, IN607B2020/12 and 858014. J.F.L. is funded by Xunta de Galicia (ED481B 2017/117). M.B. was funded by MRC (MR/K501372/1). T.P.M. was funded by a QMUL PhD programme and T.D.N.’s lab is currently funded by a Barts Charity project grant (MGU0534). P.C.F. is currently funded by GAIN (IN606C 2021/006) Xunta de Galicia, Reino Unido. Biotechnology and Biological Sciences Research Council; BB/P000223/1, Reino Unido. Medical Research Council; MR/K501372/1, Reino Unido. Royal Society; RG170399, Barts Charity (Londres); MGU0497, Barts Charity (Londres); G-002158, Xunta de Galicia; IN607B2020/12, Xunta de Galicia; ED481B 2017/117, Barts Charity (Londres); MGU0534, Xunta de Galicia; IN606C 2021/006